VYYRF (Voyageur Pharmaceuticals) 3-Year RORE % : 16.67% (As of Feb. 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
14 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals 3-Year RORE %?

Voyageur Pharmaceuticals VYYRF 14 3-Year RORE % is 16.67 as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 937 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks better than 63.61% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Voyageur Pharmaceuticals's 3-Year RORE % for the quarter that ended in Feb. 2026 was 16.67%.

The industry rank for Voyageur Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

VYYRF's 3-Year RORE % is ranked better than
63.61% of 937 companies
in the Drug Manufacturers industry
Industry Median: 3.09 vs VYYRF: 16.67

Voyageur Pharmaceuticals  (OTCPK:VYYRF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Voyageur Pharmaceuticals 3-Year RORE % Related Terms


Voyageur Pharmaceuticals 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals 3-Year RORE % Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 -7.14 -3.45 0.00 40.00

Voyageur Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.33 -34.78 3.70 40.00 16.67

VYYRF vs ZTS, UTHR: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's 3-Year RORE % falls into.


VYYRF
14GF Score
Voyageur Pharmaceuticals Ltd VYYRF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals 3-Year RORE % Calculation

Voyageur Pharmaceuticals's 3-Year RORE % for the quarter that ended in Feb. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.007--0.004 )/( -0.018-0 )
=-0.003/-0.018
=16.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Feb. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 16.67 mean?
Voyageur Pharmaceuticals (VYYRF) has a 3-Year RORE % of 16.67 as of Feb. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #341 out of 937 companies in the Drug Manufacturers industry, placing it in the top 36.4%.
Is Voyageur Pharmaceuticals' 3-Year RORE % too high?
Voyageur Pharmaceuticals' current 3-Year RORE % is 16.67. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Voyageur Pharmaceuticals' value of 16.67 is 439.5% above this industry median. Based on the distribution chart, Voyageur Pharmaceuticals ranks #341 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Voyageur Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #341 out of 937 companies for 3-Year RORE %. This puts Voyageur Pharmaceuticals in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Voyageur Pharmaceuticals' value of 16.67 is 439.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voyageur Pharmaceuticals's current 3-Year RORE % of 16.67 is 439.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Voyageur Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current 3-Year RORE % is 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current 3-Year RORE % of 16.67. The current 3-Year RORE % is 16.67 and 439.5% above the Drug Manufacturers industry median of 3.09. Voyageur Pharmaceuticals' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current 3-Year RORE % is 16.67 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
14GF Score

Get the complete analysis for VYYRF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price